Doğan, AyşegülDemirci, SelamiBaşak, NeşeÇağlayan, Ahmet BurakAydın, SafaTelci, DilekKılıç, ErtuğrulŞahin, KazımOrhan, CemalTuzcu, MehmetŞahin, FikrettinDoğan Ekinci, Işın Asiye2017-04-172017-04-172016Doğan, A. Demirci, S. Başak, N. Çağlayan, A. B. Aydın, S.Telci, D. Kılıç, E. Şahin, K. Orhan, C. Tuzcu, M. Şahin, F. Doğan Ekinci, I. A. (2016). Schiff Base Poloxamer P85 Combination Prevents Prostate Cancer Progression in C57 Bl6 Mice . Prostate, 76:1454–1463.https://hdl.handle.net/11616/6674BACKGROUND. Prostate cancer which is the second most common cause of death among men has a high incidence in recent years. Current therapeutic regimens should be improved to overcome drug resistance. At the metastatic stage, tumors become refractory to established chemotherapeutic treatments and cause serious problems at the clinics. Development of new drug molecules that are able to transport through the membrane easily and kill tumor cells rapidly is of great interest. METHOD. In the current study, a novel Heterodinuclear copper(II)Mn(II) Schiff base complex combined with P85 was used for prostate cancer treatment in vivo. Tramp-C1 cells injected animals were subjected to chemotherapeutic formulation treatment and results were analyzed by toxicology analysis, tumor volume measurements, and histopathological analysis. 0.5 mg/kg Schiff base was selected and combined with 0.05% P85 according to the toxicology analysis showing the enzyme levels, blood parameters, and multiple organ toxicity. RESULTS. Results demonstrated that Heterodinuclear copper(II)Mn(II) complex-P85 combination decreased tumor formation and tumor volume steadily over the course of experiments. CONCLUSIONS. Overall, Heterodinuclear copper(II)Mn(II) complex-P85 exerted remarkable anti-cancer activity in vivo in C57/B16 mice. Prostate 76:1454–1463, 2016. # 2016 Wiley Periodicals, Inc.eninfo:eu-repo/semantics/openAccessSchiff basePluronicP85Prostate cancerTrampC1Article761454146310.1002/pros.23229